Home » Stocks » NVS

Novartis AG (NVS)

Stock Price: $92.69 USD -0.81 (-0.87%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 209.06B
Revenue (ttm) 49.88B
Net Income (ttm) 7.96B
Shares Out 2.25B
EPS (ttm) 3.48
PE Ratio 26.64
Forward PE 14.81
Dividend $3.40
Dividend Yield 3.67%
Trading Day June 11
Last Price $92.69
Previous Close $93.50
Change ($) -0.81
Change (%) -0.87%
Day's Open 93.26
Day's Range 92.53 - 93.26
Day's Volume 1,379,723
52-Week Range 74.07 - 94.72


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Of the equities that make up the S&P 500, only seven have market caps larger than $200 billion and pay a dividend yield of at least 3%.

Other stocks mentioned: ABBV, CVX, KO
2 days ago - 24/7 Wall Street

Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Co...

2 days ago - GlobeNewsWire

Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products.

4 days ago - Reuters

Novartis CEO on new cancer therapy programs

YouTube video

CNBC's Meg Tirrell talks to Dr. Vasant Narasimhan, CEO of Novartis, about his company's new cancer therapy, which uses targeted microdoses of radiation to combat cancer. For access to live and exclusive...

6 days ago - CNBC Television

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

6 days ago - Zacks Investment Research

Novartis AG (NYSE: NVS) announced data from Phase 2 trial evaluating iptacopan (LNP023) in rare kidney disease IgA nephropathy (IgAN). Data were presented at the 58th ERA-EDTA Congress.

6 days ago - Benzinga

Basel, June 0 6 , 20 2 1 — Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in t...

1 week ago - GlobeNewsWire

Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide LAR in patients with midgut neuroendoc...

1 week ago - Benzinga

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

1 week ago - Zacks Investment Research

Basel, June 4, 2021 — Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult pati...

1 week ago - GlobeNewsWire

Basel, June 4, 2021 — Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall surv...

1 week ago - GlobeNewsWire

Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) in patients with progressive PSMA-posi...

1 week ago - Benzinga

Basel, June 3, 2021 — Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated signifi...

1 week ago - GlobeNewsWire

Here's one genetics play that you might want to put on your radar.

Other stocks mentioned: ALNY, NTLA, PFE, REGN
1 week ago - The Motley Fool

Basel, June 2, 2021 — Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients with relapsed or refractory (r/r) foll...

1 week ago - GlobeNewsWire

Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of symptoms compared to placebo in ped...

1 week ago - Benzinga

The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy or ph...

1 week ago - Benzinga

Basel, June 2, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) sig...

1 week ago - GlobeNewsWire

Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after more frequent dosing intervals were asso...

1 week ago - Benzinga

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Other stocks mentioned: MLLCF
2 weeks ago - Zacks Investment Research

Novartis AG (NYSE: NVS) along with Molecular Partners AG (OTC: MLLCF) is kicking off a Phase 2/3 EMPATHY study of DARPin therapeutic candidate, ensovibep (MP0420), to treat COVID-19. The program is inve...

Other stocks mentioned: MLLCF
2 weeks ago - Benzinga

Basel, May 27, 2021 — Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovi...

2 weeks ago - GlobeNewsWire

Basel, May 19, 2021 — Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 American Society of ...

3 weeks ago - GlobeNewsWire

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz...

Other stocks mentioned: AMGN
3 weeks ago - Benzinga

Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Da...

3 weeks ago - Benzinga

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

Other stocks mentioned: ABBV, AZN, JNJ, LLY, MRK, PFE
1 month ago - Zacks Investment Research

The following three stocks may be of interest to dividend investors, as they are offering much higher dividend yields than the S&P 500 Index. The benchmark index's dividend yields 1.38% as of Friday, Ap...

Other stocks mentioned: ABBV, CVX
1 month ago - GuruFocus

Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year...

1 month ago - Benzinga

Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular e...

1 month ago - GlobeNewsWire

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during the first quarter of 2021, which ended on March 31.

Other stocks mentioned: PFE
1 month ago - GuruFocus

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

Other stocks mentioned: ABBV, BMY, GILD, GSK, JNJ, MRK
1 month ago - InvestorPlace

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

1 month ago - Zacks Investment Research

It was partially because of COVID-19.

1 month ago - The Motley Fool

Novartis earnings and revenue came in below first-quarter estimates, with the Swiss drug giant guiding to modest 2021 growth. Novartis stock edged lower.

1 month ago - Investors Business Daily

A Milan judge on Tuesday indicted the Italian units of Novartis and Bayer on charges of operating a scheme to cheat the regional public health service in Lombardy, legal and judicial sources said.

Other stocks mentioned: BAYRY
1 month ago - Reuters

Novartis AG (NYSE: NVS) Q1 core net income dropped 4% Y/Y, as COVID-19 related lockdowns and disruptions around the globe hit demand. Novartis missed earnings and sales expectations as the pandemic hit ...

1 month ago - Benzinga

Innovative medicines business returning to growth, Novartis CEO says

YouTube video

Novartis CEO Vas Narasimhan discusses the pharmaceutical company's first-quarter earnings and the outlook for drug approvals in 2021.

1 month ago - CNBC International TV

Novartis CEO: Health care systems are rebounding in U.S.

YouTube video

Novartis CEO Vas Narasimhan discusses the return of health care systems following the height of the coronavirus pandemic and the pharma giant's M&A strategy for 2021.

1 month ago - CNBC International TV

Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference ...

Other stocks mentioned: CVAC
1 month ago - Reuters

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%, missing analyst expectations, as COVID-19 related lockdowns and disruptions around the globe hit demand.

1 month ago - Reuters

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Other stocks mentioned: RHHBY
1 month ago - Zacks Investment Research

These brand-name companies with $200 billion-plus market caps still have plenty of gas in the tank.

Other stocks mentioned: AMZN, BABA, CRM, NKE
1 month ago - The Motley Fool

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.

2 months ago - Zacks Investment Research

Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million...

2 months ago - Benzinga

Arix Bioscience PLC (LON:ARIX) said its portfolio company Artios Pharma Limited, in which it owns a 12.4% stake, has agreed a global research collaboration with Swiss pharma giant Novartis to create a n...

2 months ago - Proactive Investors

Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of rad...

2 months ago - Benzinga

The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.

2 months ago - Zacks Investment Research

Johnson & Johnson's (NYSE:JNJ) 2020 revenue topped all pharmaceutical companies, according to rankings published by Fierce Pharma.

Other stocks mentioned: JNJ, RHHBY
2 months ago - GuruFocus

Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclero...

Other stocks mentioned: GMAB
2 months ago - Benzinga

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents inclu...

2 months ago - GlobeNewsWire

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to... [Read more...]

Drug Manufacturers-General
IPO Date
Nov 18, 1991
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, Novartis's revenue was $49.90 billion, an increase of 2.51% compared to the previous year's $48.68 billion. Earnings were $8.07 billion, a decrease of -31.20%.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Novartis stock is "Strong Buy." The 12-month stock price forecast is 105.13, which is an increase of 13.42% from the latest price.

Price Target
(13.42% upside)
Analyst Consensus: Strong Buy